Response to: The safety and efficacy, and recommendations for the use of biologic drugs in the UK military rheumatology population

I read with dismay article by Bennet et al as while the clinical content was informative and extremely useful the authors go on to make recommendations about the medical employment standards of these patients. This is out with current policy. This may lead to individual service personnel having career expectations which may not be realised and risks medico-legal action.

Tri-service direction on the appropriate Joint Medical Employment Standard for those patients on antitumour necrosis...
factors and other disease modifying anti-rheumatic drugs (DMARDs) is published in JSP 950 6-7-6. This has just been reviewed and advises that patients on DMARDs should be graded no higher than Medically Limited Deployability.\(^4\) However, the readership should be aware that this can vary between the Single Services. Clinicians are therefore advised to refer these patients to the Regional Occupational Health Team for advice about management. Currently, Army Occupational Medicine would advise a grading of no higher than P7 MLD for the majority of these patients.\(^5\)

Lt Col Sarah Jackson  
**Correspondence to**  Sarah Jackson, Army Medical Directorate, Army Headquarters, Marlborough Lines, Andover, Hants SP11 8HJ, UK; drsarahjackson@live.co.uk

**Competing interests**  None.

**Provenance and peer review**  Not commissioned; internally peer reviewed.

**To cite**  Jackson LCS. *J R Army Med Corps* 2013;159:315–316.

Received 10 May 2013  
Accepted 10 May 2013  
Published Online First 3 July 2013

doi:10.1136/jramc-2013-000107

**REFERENCE**

   *J R Army Med Corps* 2013;159:8–14.


Response to: The safety and efficacy, and recommendations for the use of biologic drugs in the UK military rheumatology population

Lt Col Sarah Jackson

J R Army Med Corps 2013 159: 315-316 originally published online July 3, 2013
doi: 10.1136/jramc-2013-000107

Updated information and services can be found at:
http://jramc.bmj.com/content/159/4/315

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/